menu
    • menu
    [{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Medison"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Not Applicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Not Applicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Radium-224

    Menu

    Radium-224

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

                            Details : Alpha Dart (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 17, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approva...

                            Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metas...

                            Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceptance in Major Peer-Reviewed Journals of Two Landmark Pre-Clinical Studies

                            Details : Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2022

                            Lead Product(s) : Radium-224,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

                            Details : Alpha DaRT is based on inserting directly into tumor small amounts of radium-224 affixed to metal sources designed to decay and release radioactive atoms that diffuse inside tumor, emitting alpha radiation that aims to damage and kill cancer cells within...

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2022

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

                            Details : Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

                            Details : Alpha DaRT (Radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral insertion of radium-224 impregnated seeds.

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulat...

                            Details : The investigators will examine whether such a synergy exists between Alpha DaRT, immune checkpoint inhibitors, and biological treatments that inhibit DNA repair in a pre-clinical setting.

                            Brand Name : Alpha Dart

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 20, 2022

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Oncoinvent

                            Norway arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine

                            Details : Radspherin®, a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities and its versatility allows it to be deployed for the treatment of a variety of cancer indications.

                            Brand Name : Radspherin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2021

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Oncoinvent

                            Norway arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Safety Monitoring Committee Recommends 7 MBq as Clinical Dose for Radspherin in RAD-18-002 Phase 1 Trial for C...

                            Details : 7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study.

                            Brand Name : Radspherin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 09, 2021

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth